mrjСовременная ревматологияModern Rheumatology Journal1996-70122310-158XIMA-PRESS, LLC10.14412/1996-7012-2019-S2-1-8mrj-976Research ArticleФАРМАКОЭКОНОМИКАPHARMACOECONOMICSСравнительный клинико-экономический анализ применения симптоматических препаратов замедленного действия, содержащих глюкозамина сульфат, у пациентов с гонартрозом II стадии на этапе амбулаторно-поликлинической помощиComparative clinical and economic analysis of the use of symptomatic slow-acting drugs containing glucosamine sulfate in patients with Stage II gonarthrosis during outpatient careСарвилинаИ. В.SarvilinaI. V.isarvilina@mail.ruПрокофьеваЮ. С.ProkofyevaYu. S.

кафедра нервных болезней стоматологического факультета

127473, Москва, ул.. Делегатская, 20, стр. 1

3127206, Москва, ул. Вучетича, 21

Department of Nervous System Diseases, Faculty of Dentistry

20, Delegatskaya St., Build. 1, Moscow 127473

21, Vuchetich St., Moscow 127206

ООО «Медицинский центр «Новомедицина»РоссияOOO «Novomeditsina» Medical CenterRussian FederationФГБОУ ВО «Московский государственный медико-стоматологический университет им. А.И. Евдокимова» Минздрава России; Городская клиническая больница им. С.И. СпасокукоцкогоРоссияA.I. Evdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of Russia; S.I. Spasokukotsky City Clinical HospitalRussian Federation201909122019134S976Copyright © Сарвилина И.В., Прокофьева Ю.С., 20192019Сарвилина И.В., Прокофьева Ю.С.Sarvilina I.V., Prokofyeva Y.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://mrj.ima-press.net/mrj/article/view/976клинико-экономический анализглюкозамина сульфатСустагард® Артрозатраты/эффективностьclinical and economic analysisglucosamine sulfateSustaguard® Artrocost/effectivenessПубликация статьи поддержана ЗАО «ФармФирма «Сотекс»ReferencesReginster JL, Arden NK, Haugen IK, et al. Guidelines for the conduct of pharmacological clinical trials in hand osteoarthritis: Consensus of a working group of the European Society on Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal diseases (ESCEO). Semin Arthritis Rheum. 2018 Aug;48(1):1-8. doi: 10.1016/j.semarthrit.2017.12.003. Epub 2017 Dec 7.Reginster JL, Arden NK, Haugen IK, et al. Guidelines for the conduct of pharmacological clinical trials in hand osteoarthritis: Consensus of a working group of the European Society on Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal diseases (ESCEO). Semin Arthritis Rheum. 2018 Aug;48(1):1-8. doi: 10.1016/j.semarthrit.2017.12.003. Epub 2017 Dec 7.Arden N, Nevitt M. Osteoarthritis: epidemiology. Best Pract Res Clin Rheumatol. 2006 Feb;20(1):3-25. doi: 10.1016/j.berh.2005.09.007Arden N, Nevitt M. Osteoarthritis: epidemiology. Best Pract Res Clin Rheumatol. 2006 Feb;20(1):3-25. doi: 10.1016/j.berh.2005.09.007Насонова ВА, Фоломеева ОМ. Медикосоциальное значение XIII класса болезней для населения России. Научно-практическая ревматология. 2001;39(1):7-11.Nasonova VA, Folomeeva OM. Medical and social significance of the XIII class of diseases for the population of Russia. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2001;39(1):7-11. (In Russ.)Litwic A, Edwards MH, Dennison EM, Cooper C. Epidemiology and burden of osteoarthritis. Br Med Bull. 2013;105:185-99. doi: 10.1093/bmb/lds038. Epub 2013 Jan 20.Litwic A, Edwards MH, Dennison EM, Cooper C. Epidemiology and burden of osteoarthritis. Br Med Bull. 2013;105:185-99. doi: 10.1093/bmb/lds038. Epub 2013 Jan 20.Neogi T, Zhang Y. Epidemiology of osteoarthritis. Rheum Dis Clin North Am. 2013 Feb;39(1):1-19. doi: 10.1016/j.rdc.2012.10.004. Epub 2012 Nov 10.Neogi T, Zhang Y. Epidemiology of osteoarthritis. Rheum Dis Clin North Am. 2013 Feb;39(1):1-19. doi: 10.1016/j.rdc.2012.10.004. Epub 2012 Nov 10.Jordan K, Arden N, Doherty M, et al. EULAR Recommendations 2003, an evidence based approach to the management of knee osteoarthritis: report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis. 2003 Dec; 62(12):1145-55.Jordan K, Arden N, Doherty M, et al. EULAR Recommendations 2003, an evidence based approach to the management of knee osteoarthritis: report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis. 2003 Dec; 62(12):1145-55.Woolf A, Pfleger B. Burden of major musculoskeletal conditions. Bull World Health Organ. 2003;81(9):646-56. Epub 2003 Nov 14.Woolf A, Pfleger B. Burden of major musculoskeletal conditions. Bull World Health Organ. 2003;81(9):646-56. Epub 2003 Nov 14.Алексеева ЛИ. Препараты замедленного действия в лечении ОА. Русский медицинский журнал. 2012;(7):389-93.Alekseeva LI. Delayed-action drugs in the treatment of OA. Russkii meditsinskii zhurnal. 2012;(7):389-93. (In Russ.)Еловикова ЕС. Интенсивность процессов перекисного окисления липидов у больных остеоартрозом. Альманах молодой науки. 2010;(3):9-10.Elovikova ES. Intensity of lipid peroxidation processes in osteoarthritis patients. Al'manakh molodoi nauki. 2010;(3):9-10. (In Russ.)Ishijima M, Watari T, Naito K, et al. Relationships between biomarkers of cartilage, bone, synovial metabolism and knee pain provide insights into the origins of pain in early knee osteoarthritis. Arthritis Res Ther. 2011 Feb 14;13(1):R22. doi: 10.1186/ar3246.Ishijima M, Watari T, Naito K, et al. Relationships between biomarkers of cartilage, bone, synovial metabolism and knee pain provide insights into the origins of pain in early knee osteoarthritis. Arthritis Res Ther. 2011 Feb 14;13(1):R22. doi: 10.1186/ar3246.Murray CJ, Vos T, Lozano R, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012 Dec 15;380(9859):2197-223. doi: 10.1016/S0140-6736(12)61689-4.11 Murray CJ, Vos T, Lozano R, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012 Dec 15;380(9859):2197-223. doi: 10.1016/S0140-6736(12)61689-4.Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1,160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012 Dec 15;380(9859):2163-96. doi: 10.1016/S0140-6736(12)61729-2.Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1,160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012 Dec 15;380(9859):2163-96. doi: 10.1016/S0140-6736(12)61729-2.Symmons D, Mathers C, Pfleger B. Global burden of osteoarthritis in the year 2000. www.who.int/entity/healthinfo/statistics/bod_osteoarthritis.pdfSymmons D, Mathers C, Pfleger B. Global burden of osteoarthritis in the year 2000. www.who.int/entity/healthinfo/statistics/bod_osteoarthritis.pdfMathers C, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006 Nov;3(11):e442.Mathers C, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006 Nov;3(11):e442.Fernandes L, Hagen K, Bijlsma J, et al. EULAR Reco mmendations for the Nonpharmacological Core Management of Hip and Knee Osteoarthritis. Ann Rheum Dis. 2013 Jul;72(7):1125-35. doi: 10.1136/annrheumdis-2012-202745. Epub 2013 Apr 17.Fernandes L, Hagen K, Bijlsma J, et al. EULAR Reco mmendations for the Nonpharmacological Core Management of Hip and Knee Osteoarthritis. Ann Rheum Dis. 2013 Jul;72(7):1125-35. doi: 10.1136/annrheumdis-2012-202745. Epub 2013 Apr 17.Лесняк ОМ, редактор. Клинические рекомендации. Остеоартрит. Диагностика и ведение больных остеоартритом коленных и тазобедренных суставов. Москва: ГЭОТАР-Медиа; 2006.Lesnyak OM, editor. Klinicheskie rekomendatsii. Osteoartrit. Diagnostika i vedenie bol'nykh osteoartritom kolennykh i tazobedrennykh sustavov [Clinical recommendations. Osteoarthritis. Diagnosis and management of patients with osteoarthritis of the knee and hip joints]. Moscow: GEOTAR-Media; 2006Зайцева ЕМ, Алексеева ЛИ, Насонов ЕЛ. Патогенез остеоартроза и обоснование применения стронция ранелата. Научно-практическая ревматология. 2013;51(6):696–702. doi:10.14412/1995-4484-2013-696-702.Zaitseva EM, Alekseeva LI, Nasonov EL. Pathogenesis of osteoarthritis and substantiation of the use of strontium ranelate. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2013;51(6):696–702. (In Russ.) doi:10.14412/1995-4484-2013-696-702.Белоусов ЮБ, Лепахин ВК, Кукес ВГ, Петров ВИ, редакторы. Клиническая фармакология. Национальное руководство. Москва: ГЭОТАР-Медиа; 2009.Belousov YuB, Lepakhin VK, Kukes VG, Petrov VI, editors. Klinicheskaya farmakologiya. Natsional'noe rukovodstvo [Clinical pharmacology. National guidelines]. Moscow: GEOTAR-Media; 2009.Савелова ЕЕ, Майко ОЮ. Рациональная терапия остеоартроза в амбулаторных условиях. Клиницист. 2012;(3-4):67-72.Savelova EE, Maiko OYu. Rational therapy of osteoarthritis on an outpatient basis. Klinitsist. 2012;(3-4):67-72. (In Russ.)Rozendaal RM, Koes BW, van Osch GJ, et al. Effect of glucosamine sulfate on hip osteoarthritis: a randomized trial. Ann Intern Med. 2008 Feb 19;148(4):268-77.Rozendaal RM, Koes BW, van Osch GJ, et al. Effect of glucosamine sulfate on hip osteoarthritis: a randomized trial. Ann Intern Med. 2008 Feb 19;148(4):268-77.Голубев Г, Кригштейн О. Молекулярная патология остеоартроза как основа для создания патогенетически обоснованной структурно-модифицирующей терапии. Международный журнал медицинской практики. 2005;(2):30-8Golubev G, Krigshtein O. Molecular pathology of osteoarthritis as a basis for pathogenetically justified structural-modifying therapy. Mezhdunarodnyi zhurnal meditsinskoi praktiki. 2005;(2):30-8. (In Russ.)Setnikar I, Cereda R, Pacini A, et al. Antireactive properties of glucosamine sulfate. rzneimittelforschung. 1991 Feb;41(2): 157-61.Setnikar I, Cereda R, Pacini A, et al. Antireactive properties of glucosamine sulfate. rzneimittelforschung. 1991 Feb;41(2): 157-61.McAlindon Т, La Valley M, Gulin J, Felson D. Glucosamine and chondroitin for treatment of osteoarthritis: a systematic quality assessment and meta-analysis. JAMA. 2000 Mar 15;283(11):1469-75.McAlindon Т, La Valley M, Gulin J, Felson D. Glucosamine and chondroitin for treatment of osteoarthritis: a systematic quality assessment and meta-analysis. JAMA. 2000 Mar 15;283(11):1469-75.Towheend ТЕ, Anastassiades TP, Shea B, et al. Glucosamine therapy for treating osteoarthritis. Cochrane Database Syst Rev. 2001;(1):CD002946.Towheend ТЕ, Anastassiades TP, Shea B, et al. Glucosamine therapy for treating osteoarthritis. Cochrane Database Syst Rev. 2001;(1):CD002946.Об утверждении отраслевого стандарта «Клинико-экономические исследования. Общие положения»: приказ №163 Министерства Здравоохранения Российской Федерации от 27.05.2011. [On approval of the industry standard «Clinical and economic research. General provisions»: order №163 of the Ministry of Health of the Russian Federation from 27.05.2011].Об утверждении отраслевого стандарта «Клинико-экономические исследования. Общие положения»: приказ №163 Министерства Здравоохранения Российской Федерации от 27.05.2011. [On approval of the industry standard «Clinical and economic research. General provisions»: order №163 of the Ministry of Health of the Russian Federation from 27.05.2011].Смирнов АВ. Атлас рентгенологической диагностики первичного остеоартроза. Москва: ИМА-ПРЕСС; 2010.Smirnov AV. Atlas rentgenologicheskoi diagnostiki pervichnogo osteoartroza [Atlas of x-ray diagnosis of primary osteoarthritis]. Moscow: IMA-PRESS; 2010Kellgren JH, Lawrence JS. Radiographic assessment of osteoarthritis. Ann Rheum Dis. 1957 Dec;16(4):494-502.Kellgren JH, Lawrence JS. Radiographic assessment of osteoarthritis. Ann Rheum Dis. 1957 Dec;16(4):494-502.Государственный реестр лекарственных средств. [State register of medicines] http://grls.rosminzdrav.ruГосударственный реестр лекарственных средств. [State register of medicines] http://grls.rosminzdrav.ruhttps://www.pharmindex.ruhttps://www.pharmindex.ruhttp://government.ru/docs/35025/http://government.ru/docs/35025/http://rostov-tfoms.ru/dokumenty/normativnaya-baza/tarifnoe-soglasheniehttp://rostov-tfoms.ru/dokumenty/normativnaya-baza/tarifnoe-soglashenieГерасимов ВБ, Хохлов АЛ, Карпов ОИ, редакторы. Фармакоэкономика и фармакоэпидемиология – практика приемлемых решений. Москва: Медицина; 2005.Gerasimov VB, Khokhlov AL, Karpov OI, editors. Farmakoekonomika i farmakoepidemiologiya – praktika priemlemykh reshenii [Pharmacoeconomics and pharmacoepidemiology-practice of acceptable solutions]. Moscow: Meditsina; 2005Walley T, Haycox A, Boland A. Pharmacoeconomics. Elsevier Health Sciences; 2004.Walley T, Haycox A, Boland A. Pharmacoeconomics. Elsevier Health Sciences; 2004.

The authors declare that there are no conflicts of interest present.